· Singmed self-developed product

· Multi-dose Blister DPI

· Singmed’s self-developed Diskus® devices (loaded with Umeclidinium Bromide and Vilanterol Trifenatate produced by GSK) have passed Bioequivalence Evaluation in 2022.

· Singmed’s self-developed Diskus® (loaded with Salmeterol Xinafoate and Fluticasone Propionate Powder for Inhalation produced by GSK) has been conductingBioequivalence researching with a number of Chinese leading listed pharmaceutical companies.

· With a distinctive product appearance, the atomization performance and the aerodynamic basis of our device are proved to be equivalent to the novel product, allowing for replacement of the patented device (Seretide® Diskus® produced by GSK). We are capable of providing customers with integrated customized services encompassing research and development, design, and production.

· Counting window for accurate indication of dosage

· Easy/Effortless compliance management. Suitable/ Appropriate for the elderly, Childrens and individuals with limited respiratory capacity.

· Inspiratory resistance range 0.03 to 0.06（kPa·s/L）